| 1F16 | A:1-192 | SOLUTION STRUCTURE OF A PRO-APOPTOTIC PROTEIN BAX |
| 1G5J | A:1-215 | COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD |
| 1G5M | A:3-207 | HUMAN BCL-2, ISOFORM 1 |
| 1GJH | A:3-207 | HUMAN BCL-2, ISOFORM 2 |
| 1LXL | A:-3-217 | NMR STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH, MINIMIZED AVERAGE STRUCTURE |
| 1MAZ | A:1-196 | X-RAY STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH |
| 1MK3 | A:1-178 | SOLUTION STRUCTURE OF HUMAN BCL-W PROTEIN |
| 1O0L | A:-4-183 | THE STRUCTURE OF BCL-W REVEALS A ROLE FOR THE C-TERMINAL RESIDUES IN MODULATING BIOLOGICAL ACTIVITY |
| 1R2D | A:1-196 | STRUCTURE OF HUMAN BCL-XL AT 1.95 ANGSTROMS |
| 1R2E | A:2-196 | HUMAN BCL-XL CONTAINING A GLU TO LEU MUTATION AT POSITION 92 |
| 1R2G | A:1-196 | HUMAN BCL-XL CONTAINING A PHE TO TRP MUTATION AT POSITION 97 |
| 1R2H | A:1-196 | HUMAN BCL-XL CONTAINING AN ALA TO LEU MUTATION AT POSITION 142 |
| 1R2I | A:1-197 | HUMAN BCL-XL CONTAINING A PHE TO LEU MUTATION AT POSITION 146 |
| 1YSG | A:1-221 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN COMPLEX WITH "SAR BY NMR" LIGANDS |
| 1YSI | A:1-221 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
| 1YSN | A:1-221 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL COMPLEXED WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
| 1YSW | A:1-204 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-2 COMPLEXED WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
| 2BID | A:1-197 | HUMAN PRO-APOPTOTIC PROTEIN BID |
| 2K7W | A:1-192 | BAX ACTIVATION IS INITIATED AT A NOVEL INTERACTION SITE |
)
)